64 phenotypes from 2 alleles in 5 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Csf2tm1Ard/Csf2tm1Ard involves: 129P2/OlaHsd * C57BL/6	abnormal alveolar macrophage morphology	J:18747
	abnormal fertility/fecundity	J:53659
	abnormal leukocyte physiology	J:86386
	abnormal lung morphology	J:18747
	abnormal MHC II cell surface expression on macrophages	J:86386
	abnormal ovulation	J:86386
	abnormal placenta development	J:53659
	abnormal pulmonary alveolus morphology	J:18747
	abnormal spleen size	J:67766
	abnormal uterus morphology	J:53659
	absent mature ovarian follicles	J:86386
	decreased body size	J:53659
	decreased circulating progesterone level	J:86386
	decreased fetal size	J:53659
	decreased litter size	J:53659
	decreased ovary weight	J:86386
	decreased trophoblast glycogen cell number	J:53659
	emphysema	J:18747
	fetal growth retardation	J:53659
	normal hematopoietic system phenotype	J:18747
	impaired luteinization	J:86386
	impaired macrophage chemotaxis	J:86386
	increased spongiotrophoblast size	J:53659
	increased susceptibility to bacterial infection	J:18747, J:53659
	increased susceptibility to fungal infection	J:18747
	increased susceptibility to parasitic infection	J:67766
	lung inflammation	J:18747
	lymphoid hyperplasia	J:18747
	maternal effect	J:53659
	perinatal lethality, incomplete penetrance	J:53659
	placental labyrinth hypoplasia	J:53659
	postnatal growth retardation	J:53659
	postnatal lethality, incomplete penetrance	J:53659
	prenatal lethality, incomplete penetrance	J:53659
	prolonged diestrus	J:86386
	prolonged estrous cycle	J:86386
	prolonged metestrus	J:86386
	pulmonary alveolar proteinosis	J:18747
	reduced fertility	J:53659
Csf2tm1Mlg/Csf2tm1Mlg B6.129S2-Csf2tm1Mlg	abnormal abdominal fat pad morphology	J:102499
	abnormal lipid level	J:102499
	abnormal pancreatic islet morphology	J:145518
	normal behavior/neurological phenotype	J:102499
	decreased energy expenditure	J:102499
	increased abdominal adipose tissue amount	J:102499
	increased body weight	J:102499
	increased circulating free fatty acids level	J:102499
	increased circulating glucose level	J:145518
	increased circulating leptin level	J:102499
	increased circulating triglyceride level	J:102499
	increased food intake	J:102499
	increased gonadal fat pad weight	J:102499
	increased mesenteric fat pad weight	J:102499
	increased subcutaneous adipose tissue amount	J:102499
	increased total body fat amount	J:102499
Csf2tm1Mlg/Csf2tm1Mlg involves: 129S2/SvPas	abnormal alveolar macrophage morphology	J:17978
	abnormal lung morphology	J:17978
	abnormal pulmonary alveolus morphology	J:17978
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:148120
	normal hematopoietic system phenotype	J:17978
	lymphoid hyperplasia	J:17978
	normal mortality/aging	J:17978
Csf2tm1Mlg/Csf2tm1Mlg involves: 129S2/SvPas * BALB/c	abnormal aorta collagen fibril morphology	J:84697
	abnormal aorta elastic fiber morphology	J:84697
Csf2tm1Mlg/Csf2tm1Mlg involves: 129S2/SvPas * C57BL/6	abnormal circulating glucose level	J:142440
	abnormal mesenteric fat pad morphology	J:142440
	decreased circulating insulin level	J:142440
	enhanced gluconeogenesis	J:142440
	increased body weight	J:142440
	increased fat cell size	J:142440